• +977-1-4003006/7
  • info@nitapolyclinic.com.np
First Trimester Quad Screen Test

First Trimester Quad Screen Test

First Trimester Quad Screen prenatal screening by AutoDELFIA immunoassay system is reliable and high-quality results both for aneuploidy and pre-eclampsia risk assessment during pregnancy



First Trimester Quad Screen with NT (Nuchal Translucency) and preeclampsia (from 11 to 13 weeks of pregnancy) for pregnant women as this test to classify a patient as either high-risk or low-risk for chromosomal abnormalities (Down Syndrome-Trisomy 21, Edward’s Syndrome-Trisomy 18) and neural tube defects, which helps clinicians in early diagnosis.

Earlier risk assessment of other pregnancy complications like pre-eclampsia.

Pre-eclampsia occurs in around 1 in 50 pregnancies. It is pregnancy induced high blood pressure and is one of the most common life-threatening conditions occurring in pregnancy.

This test not only for women of age 35 years or more. Every pregnant woman is advised to take this test, for detecting any abnormality in the fetus before birth.

Auto Delfia (Time Resolved Fluorescence) Method Results tell us whether it is a high or low risk baby up with up to 90% detection rate.

Tests Parameter to check for:

Non-invasive blood screening process is simple and involves an ultrasound scan to measure the placental blood flow at 11-13 weeks gestation in combination with maternal history, mean arterial blood pressure, serum AFP, Beta-hCG, PAPP-A maternal blood marker and placental growth factor (PLGF)

  • AFP is a protein which is produced by the fetus. If the levels of AFP are high, it indicates neural tube defects in the fetus or there can be incomplete closure of the fetus abdomen.
  • Increased Beta-hCG levels are associated with an increased risk for Down Syndrome
  • PAPP-A: Decreased levels of PAPP-A can be seen in pregnancies affected with Down syndrome in the first trimester of the pregnancy.
  • Placental growth factor (PLGF) is an important molecule in the prediction, diagnosis and treatment of pre-eclampsia. It has pro-angiogenic effects on the feto-placental circulation and supports trophoblast growth.
  • The NT (Nuchal Translucency), an ultrasound marker is important component for combined trisomy 21 risk assessment
  • Provides comprehensive reporting with graphs for better understanding


Fasting not mandatory. 3 ml. (2 ml. Minimum) Serum from 1 SST (Gel Barrier Tube)

Reported on

5 working days


Test Preparation

  • Test is valid between 11-13+6 weeks of gestation.
  • Hard copy of your latest pregnancy ultrasound report (CRL, NT/NB or Level 1),
  • Both Right & Left Blood pressure
  • Both Right & Left Uterine artery Pulsatile Index ((For Pre-eclampsia screening only)
  • Maternal Screen details (LMP, DOB, Body Weight, Diabetic status & IVF) ready at the time of your test.

The lab technician will collect blood sample from the patient. This will be processed in a lab and the report provided usually Fourth day via SMS and Email.

For Home/Office Sample Collection Call 980183093/5, 9801036380(WhatsApp)

NRS. 6400 NRS. 6500

Our Partners & Clients